Business
SOHM, Inc. Announces Allowance of Another Divisional Patent in the Republic of South Korea
SOHM, Inc. Announces Allowance of Another Divisional Patent in the Republic of South Korea.
About this update from Sohm, Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n SOHM, Inc. Announces Allowance of Another Divisional Patent in the Republic of South Korea\r\n \r\n \r\n\r\n\r\nSOHM, Inc. Announces Allowance of Another Divisional Patent in the Republic of South Korea\r\n\r\n\r\n\r\n\r\n\r\nCHINO HILLS, CALIFORNIA / ACCESS Newswire / September 15, 2025 / SOHM, Inc. (OTCID:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, a leader in Gene Editing and Cell Engineering is pleased to announce that it has received a Notice of Allowance/Approval from the South Korea Patent Office for its innovative technology entitled - \"CAS9 Retroviral Integrase and CAS9 Recombinase Systems for Targeted Incorporation of a DNA Sequence into a Genome of a Cell or Organism\"\r\n Patent Application No. 10-2024-7041475\r\n This patent builds on our growing global IP portfolio around the ABBIE gene-editing platform, which fuses dCas9 with retroviral integrases. Dr. David Aguilar said.\r\n Following earlier successes in Europe, this Korean allowance reinforces ABBIE's potential as a first-in-class solution for site-specific integration - a critical step toward developing next-generation allogeneic CAR-T therapies, regenerative medicine, and beyond.\r\n At SOHM, we remain committed to building a global intellectual property estate that secures our innovations and drives partnerships worldwide.\r\n For more information about SOHM Inc. and its groundbreaking work in biotechnology, please visit www.SOHM.com.\r\n About SOHM, Inc.:\r\n SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. SOHM strives to transform the landscape of genome editing and improve the quality of life through scientific discovery.\r\n For further information regarding this announcement or to explore potential collaborations, please contact:\r\n SOHM, Inc.:Name: Baron Night, CEO/Dr. David Aguilar, COOEmail: [email protected]: (714) 522-6700\r\n Safe Harbor Statement:\r\n This news ...